Posts

ArsenalBio cuts 99 jobs in pivot to in vivo CAR-T

on

Novartis and BMS pause autoimmune CAR-T trials after serious immune-related events

on

Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion

on

FDA Grants Orphan Drug Designation to Gamgertamig for Pemphigus

on

Scarring and Autoimmune Diseases Biotech BirchBioMed Files for Direct Nasdaq Listing

on

Boulevard Bio launches with $65M to target IgAN and other autoimmune diseases with quarterly‑dosed BAFF/APRIL bispecific against Vera's Trutakna

on

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

on

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

on

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

on

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on

Miltenyi Bio's CAR-T Clears Triple Autoimmune Burden in Single Patient

on

Sanofi's $180 Million Investment in Kali Therapeutics for T-Cell Engager Development

on

Gilead Acquires Ouro Medicines for Up to $2.18 Billion to Advance T Cell Engager Autoimmune Therapies

on

Sanofi Inks $2.56 Billion Autoimmune Bispecific Deal with Earendil Labs

on

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

on

Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering (Upsized from Initial Plans)

on

Eli Lilly Acquires Orna Therapeutics for Up to $2.4 Billion to Advance In Vivo CAR-T Therapies

on

Lilly Invests $85M Upfront in Repertoire Immune Medicines for Autoimmune Therapies Partnership

on

Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer

on